INTRODUCTION
Animal tumor models are frequently used in screening and optimizing of lead compounds in cancer drug discovery programs (1, 7) . Although the value of animal tumor models in predicting clinical efficacy is frequently debated, it is common practice to use 1 or more rodent tumor models to characterize in vivo efficacy once antitumor effects have been demonstrated in vitro. Over the last 2 decades, the drug screening strategy of the National Cancer Institute has evolved from primary screening in the mouse leukemia/lymphoma models to a disease-oriented primary screen of 60 human tumor cell lines in vitro followed by a secondary screen using human tumor xenografts in nude mice (4) . The focus of early in vivo screens is to detect efficacy characterized by improved survival, reduced tumor growth, or cures.
Once lead compounds have shown promising antitumor effects in vitro and in vivo, it becomes practical and prudent to explore pharmacokinetic and pharmacodynamic properties while evaluating antitumor activity in additional animal tumor models (3) . Toxic effects in normal tissues are readily apparent when evaluating cytotoxic drugs in efficacy models; however, toxicity may be much less important for screening cancer drugs for antiangiogenic, antimetastatic, or antihormonal activity. Efficacy studies conducted at the maximum tolerated dose provide the opportunity to obtain preliminary information on cause of death, target organs of toxicity, reversibility, and relationships between toxicity and pharmacokinetic parameters. Experimental pathologists working in oncology drug discovery programs help to characterize animal tumor models (molecular target expression) and antitumor effects (morphology, cell proliferation, apoptosis) but also have the opportunity to gather preliminary evidence of toxicity in normal tissues.
MINIMAL ASSESSMENT FOR TOXICITY
Quantities of lead compounds are frequently in short supply when early efficacy studies are conducted in animal tumor models. Therefore, although small numbers of animals per group may compromise the statistical power of numerical data, minimal information on toxicity can easily be obtained. A minimum data set may include mortality, body weight change, clinical observations, necropsy findings, and routine histopathologic examination of major organ systems (kidney, liver, heart, lung, spleen, intestine, and bone marrow). The list of organs for microscopic examination can be reduced or expanded depending on clinical observations, necropsy findings, and the mechanism of action.
Whereas intraperitoneal administration may be sufficient for proof-of-concept studies in early discovery, this route may seriously complicate the interpretation of efficacy and toxicity. If the formulation is irritating to the peritoneum, local effects of the vehicle may be confused with drug-related toxicity. If the compound is poorly absorbed, lack of efficacy may be misinterpreted as poor antitumor activity. A pathologic evaluation and plasma concentration data help to establish the validity of the experimental model.
The minimal assessment of toxicity is often sufficient to determine cause of death and organs with dose-limiting toxicity. With corresponding information on pharmacokinetics and efficacy, this preliminary toxicology data may help in prioritizing lead compounds for further study.
EXPANDED ASSESSMENT FOR TOXICITY
When early efficacy studies have identified a drug development candidate, additional studies may be appropriate to further characterize effects of formulation, route, dose, and schedule (7) . Efficacy studies of increasing duration and sophistication provide new information on potential toxic effects (1) . Whereas human tumor xenograft models may be adequate for the first in vivo screens, orthotopic models and rat tumor models provide a more complete picture of the utility of a new drug. Efficacy studies in rats provide preliminary toxicokinetic and toxicologic data that may obviate the need for dose-variable studies in rats.
As the pharmacokinetic profile of a drug candidate is clarified, both efficacy and toxicity can be more closely correlated with the pharmacokinetic parameters, Cmax, area under the curve, and time above threshold concentration. If tumors and target organs of toxicity have differing sensitivity to drug exposure, then the route, formulation, and dosage schedules may be adjusted to improve the therapeutic index (3) . At this stage in drug discovery, it may be practical to expand the pathologic assessment to include clinical pathology and characterization of tumor cell kinetics. However, clinical pathology parameters sometimes vary widely in tumor efficacy models because of the effects of tumor growth factors or ulceration and necrosis associated with large tumors. Additionally, hematologic values obtained from tumor-bearing nude mice are not always predictive for normal mice or nonrodents. Studies exploring the effect of dosing schedule provide preliminary information on how the drug candidate can be used clinically. Sustained dosing may reveal evidence of tumor resistance, cumulative toxicity, reduced metastasis, or cures. Courses of treatment interrupted by periods of recovery provide the first evidence of the reversibility of clinical and pathologic end points of toxicity. The daily dosing schedule and total dose can have a profound effect on the response to cytotoxic anticancer drugs. In summary, a comprehensive preclinical oncology drug discovery program can provide valuable pharmacokinetic, pharmacodynamic, and toxicologic information for planning the preclinical toxicology and clinical development programs (6) .
ADDITIONAL ASSESSMENTS
Efficacy studies in animal tumor models provide specimens for early assessment of liver enzyme induction, drug accumulation, and differential gene expression. Routine collection in efficacy studies of liver for histopathology also provides fresh samples for evaluation of cytochromes P450. Identification of P450 induction or suppression in early drug discovery provides additional information for prioritizing lead compounds. As genechip technology comes into common use in preclinical toxicology; samples of normal tissues collected from rodent efficacy studies at necropsy may be screened for early indicators of unexpected toxicity.
CONCLUSION
In traditional discovery and development of new chemotherapeutic agents, the preclinical toxicology program was initiated when a promising development candidate had been identified in drug discovery. Industry competition and increasing emphasis on efficiency and cost effectiveness has blurred the boundaries between discovery, preclinical development, and clinical development programs (5) . Disciplines such as pathology, toxicology, pharmacokinetics, and study of drug metabolism are now involved in screening and decision making earlier in the process. Numbers of in vivo studies may be reduced but the total amount of information obtained for the discovery and development programs may be expanded. Preliminary assessment of toxicity in animal tumor models is in no way intended to replace the preclinical toxicology program required to support clinical studies (2); however, the potential exists for early toxicity assessments to improve screening of lead compounds and provide for better planning of toxicology studies and clinical trials.
